Moderna and Eli Lilly headline global life sciences
Innovative leaders in healthcare and life sciences rely on Dechert to navigate their most complex and demanding transactional, intellectual property and litigation matters anywhere in the world.
Our work in 2021 shows many of the angles we cover for our life sciences clients.” Thomas Rayski Partner “
Whether guiding a start-up biotech through its first round of commercially significant funding, executing a strategic acquisition for a large pharmaceutical company, licensing a biotech company’s patents or winning antitrust, securities or patent disputes, our lawyers approach every matter with the resources of a major international firm and the focus and depth of a life sciences boutique. “Our work in 2021 for Moderna shows many of the angles we cover for our life sciences clients,” explains partner Thomas Rayski. “We advised Moderna in multiple licensing and partner agreements, including with AbCellera on mRNA-encoded antibody therapeutics, and Autolus to develop new mRNA cancer therapeutics. These follow agreements last year with Vertex to treat cystic fibrosis using gene editing and Chiesi Group to develop mRNA therapeutics for pulmonary arterial hypertension.” This close relationship also involves Dechert advising Moderna on
“Lilly achieved a string of victories in U.S. courts on the East and West coasts in the Fall of 2021, authorizing worldwide discovery from Novartis for use in foreign proceedings,” explains partner Kassie Helm. “Our representation of Lilly is a successful example of cross-office, cross-practice, and cross-ocean cooperation amongst our life sciences teams and with my partners Alec Burnside, George Gordon, Jonathan Loeb and Christina Sarchio.” In addition to our IP, licensing, and disputes experience in the life sciences sector, we are also considered global leaders for antitrust transactions and litigation.” Mélanie Thill-Tayara Partner “
various matters, including the highly publicized European Medicines Agency (“EMA”) data breach. “We excel in a broad range of complex transactions for life sciences clients,” says partner David Rosenthal, “including cross-border corporate and finance deals.” A highlight of 2021 was steering Tiziana Life Sciences’ migration from the Main Market of the London Stock Exchange to NASDAQ by inserting a new Bermuda-incorporated company as the parent company of the Tiziana Group. On the litigation side, Dechert is currently serving as U.S. and European counsel to Eli Lilly in global patent and antitrust litigation involving Novartis Pharma AG, which acquired and has been enforcing a Genentech portfolio against Lilly’s blockbuster antibody therapeutic Taltz® (ixekizumab). The disputes involve patent infringement and revocation claims, European Patent Office proceedings, and various antitrust claims and defenses.
“
We represent life sciences clients through all stages of the biotech life cycle – from discovery through
development and post-launch.” Andrea L. C. Reid Partner
9
Powered by FlippingBook